摘要
目的 探讨缬沙坦治疗慢性心力衰竭（CHF）对患者心功能、心室重构、基质金属蛋白酶的影响.方法 选取2014年1月至2016年1月在我院进行诊治的108例CHF患者,采用SPSS 16.0软件生成随机数字表分为观察组（基础治疗±缬沙坦）、对照组（基础治疗）各54例,疗程均为2个月,对比两组患者的临床疗效、心室重构指标、血清基质金属蛋白酶（MMP）水平变化.结果 治疗后,观察组患者的LVEF高于对照组[（48.6±4.2）％比（45.1±4.7）％]（P＜0.05）,LVEDd、LVESd、LVMI、MWS值分别为（52.3±±3.6）mm、（41.1±4.1）mm、（132.1±±6.8）g/m2、（355.0± 18.7）dmes×103/cm2,均低于对照组[（54.1±4.3）mm、（43.3±3.6）mm、（135.2±7.0）g/m2、（369.5-±21.0）dines×103/cm2]（P＜0.05）,观察组TIMP-1[（349.2±±43.7）ng/ml]高于对照组[（311.7±49.0） ng/ml]（P＜0.05）,观察组的MMP-1、MMP-9[（73.0±± 11.6）ng/ml、（139.5±±27.0）ng/ml]均低于对照组[（82.6±14.1）ng/ml、（155.2±±24.1）ng/ml] （P＜0.05）.治疗后,观察组患者显效64.81％、有效33.33％、无效1.85％,对照组显效48.15％,有效46.30％、无效5.56％,两组比较差异具有统计学意义（P＜0.05）.结论 缬沙坦治疗CHF能进一步改善患者心功能、延缓心室重构,作用机制可能与降低血清基质金属蛋白酶有关.
Objective To investigate the clinical effect of Valsartan in patients with CHF and the effects of Valsartan on ventricular remodeling and matrix metalloproteinases.Methods 108 patients with CHF who were treated in our hospital from January 2014 to January 2016 were selected,SPSS 16 software was used to generate the random number table,which was divided into observation group （basic treatment ± Valsartan） and control group（basic treatment）,each with 54 cases,the course of treatment was 2 months,compared the clinical efficacy of the two groups of patients,ventricular remodeling index,serum levels of matrix metalloproteinase（MMP） levels.Results After treatment,LVEF （48.6±4.2）％ in the observation group was higher than that in the control group （45.1±4.7）％（P＜0.05）,LVEDd,LVESd,LVMI and MWS were [（52.3±3.6）mm,（41.1±4.1）mm,（132.1±6.8）g/m2,（355.0±18.7）dmes×103/cm2],respectively,lower than control group [（54.1±4.3）mm,（43.3±3.6）mm,（135.2± 7.0）g/m2,（369.5 ±21.0）dmes x 103/cm2] （P ＜0.05）.The level of TIMP-1 （349.2±43.7） ng/ml in the observation group was higher than that in the control group （311.7±49.0）ng/ml （P＜0.05）.MMP-1,MMP-9 [（73.0±11.6）ng/ml,（139.5-±27.0）ng/ml] in the observation group were lower than those in the control group [（82.6±14.1）ng/ml,（155.2±24.1）ng/ml] （P＜0.05）.After treatment,the observation group was markedly effective 64.81％,effective 33.33％,invalid 1.85％,the control group markedly effective 48.15％,effective 46.30％,invalid 5.56％,the difference between the two groups was statistically significant （P＜0.05）.Conclusion Valsartan treatment of patients with CHF can further improve the cardiac function and delay ventricular remodeling,the mechanism may be related to the decrease of serum matrix metalloproteinase.
出处
《中国心血管病研究》
CAS
2017年第8期744-747,共4页
Chinese Journal of Cardiovascular Research
关键词
缬沙坦
慢性心力衰竭
心室重构
基质金属蛋白酶
Valsartan
Chronic heart failure
Ventricular remodeling
Matrix metalloproteinases
